Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Anaplastic thyroid carcinoma is a rare and aggressive cancer with a poor prognosis.
• Preventing suffocation is a critical management goal in anaplastic thyroid carcinoma.

Purpose of the Study:

• To evaluate the efficacy of a combined treatment regimen for anaplastic thyroid carcinoma.
• To assess the impact of hyperfractionated radiotherapy, doxorubicin, and surgery on local recurrence and survival.

Main Methods:

• A prospective study of 55 anaplastic thyroid carcinoma patients treated between 1984 and 1999.
• Combined regimen: hyperfractionated radiotherapy (varying daily fractions and total doses), weekly doxorubicin (20 mg IV), and feasible surgery.
• Three radiotherapy protocols (A, B, C) with escalating doses and different preoperative/total dose administration schedules.

Main Results:

• No treatment-related toxicity led to protocol completion failure.
• Local failure caused death in only 24% of patients.
• Overall, 60% of patients showed no signs of local recurrence (Protocol C: 77%, Protocol B: 65%, Protocol A: 31%).
• In patients undergoing surgery, 70% had no local recurrence (Protocol C: 100%, Protocol B: 79%, Protocol A: 56%).
• Survival exceeding 2 years was observed in 9% of patients.

Conclusions:

• The combined regimen of hyperfractionated radiotherapy and doxorubicin is effective in managing anaplastic thyroid carcinoma.
• Increasing radiotherapy dose and preoperative administration, particularly in Protocol C, significantly improved local control.
• The addition of surgery further enhanced local recurrence-free rates, highlighting its importance when feasible.